Leronlimab increased PD-L1 in patients with triple-negative breast cancer, potentially making cold tumors responsive to ...

Panelists discuss how investigational therapies beyond Janus kinase (JAK) inhibition, including epigenetic modulation, telomerase inhibition, PI3K/AKT/mTOR pathway inhibition, immune modulation, TGF-β ...

In type 1 diabetes, the body’s own immune system turns against the pancreas. Cells meant to protect you start destroying ...

Compass Therapeutics, Inc.’s CMPX share price has dipped by 5.62%, which has investors questioning if this is right time to buy.

Corresponding Author: Hiroyuki Suzuki, Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1, Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan. E-mail: ...

It also explores the feasibility of blocking the IL-21 signaling pathway within current immunosuppressive regimens, aiming to provide further clinical references. Figure 1. IL-21 affects a variety of ...

Department of Infectious Diseases and Hepatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, P. R. China Institute for Stem Cell & Regenerative Medicine, The Second ...

1:10 | Now this combination is not compared to directly head-to-head to single-agent IO with chemotherapy, which would be interesting to see, and probably some of the greatest benefits we're seeing ...

Pfizer’s investigational anti-PD-1 antibody significantly reduced disease events in patients with high-risk non-muscle-invasive bladder cancer, according to results from a Phase III trial. In a note ...

- Findings support advancement of ZL-6201 into Investigational New Drug (IND)-enabling studies in 2025 as a potential first-in-class and best-in-class antibody-drug conjugate (ADC) treatment for ...

Akeso has won the FDA’s go-ahead for its PD-1 inhibitor penpulimab co-developed with Sino Biopharmaceutical’s Chia Tai-Tianqing Pharmaceutical. To be marked as Anniko, penpulimab is approved ...

The researchers were interested in the effect on cancer growth of a common immunotherapy targeting a molecule called PD-1 on immune ... blocking the EPO signaling pathway and anti-PD-1 pathway.